PROOF-HD study endorsed* by EHDN

Study aims and goal: An interventional, Phase III clinical trial to evaluate the efficacy and safety of pridopidine in patients with early stage manifest Huntington’s Disease (HD). No. of study participants and sites: The study aims to recruit 480 participants at sites in: Austria, Canada, Czech Republic, France, Germany, Italy, Netherlands, Poland, Spain, UK, USA […]

Read More…

VIBRANT-HD study endorsed* by EHDN

Study aims and goal: A Randomized, double-blind, placebo-controlled dose range finding study with Open-Label Extension to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LMI070/branaplam in participants with early manifest HD. No. of study sites: This Phase IIb study aims to recruit stage 1 and 2 participants at sites in Belgium, Canada, France, Germany, Hungary, […]

Read More…